Back To: Home : Featured Technology : PCR/qPCR

CLICK HERE FOR WHAT'S NEW IN:
 

ExoLution platform better reports clinical outcome
December 2017
SHARING OPTIONS:

WALTHAM, Mass.—Exosome Diagnostics Inc. and MD Anderson Cancer Center recently published a study comparing Exosome Diagnostics’ ExoLution Plus platform with the BEAMing and ddPCR platforms. The analysis found that the ExoLution Plus platform, which analyzes exosome nucleic acids (exoNA) and cell-free DNA (cfDNA) simultaneously, better represented clinical outcome than cfDNA analysis alone in 43 patients with progressive advanced cancer. Low amounts of mutated exoNA were associated with longer survival times while high amounts were linked to shorter survival times.
 
“Our study reports two novel observations. First, our data suggest that next-generation sequencing of plasma-derived exosomal nucleic acids from patients with advanced cancers has high sensitivity compared to molecular testing of plasma cell-free DNA or archival tumor samples. Second, we demonstrated that the amount of mutated exosomal nucleic acids is an independent prognostic factor for survival,” said Filip Janku of MD Anderson Cancer Center, senior author on the study.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.